Covid-19: Zydus gets SEC approval for two-dose regimen of ZyCov-D

Zydus to conduct mixing trials to test vax efficacy after two shots of Covishield/Covaxin

Zydus Lifesciences’ (formerly known as Cadila Healthcare) three-dose Covid vaccine — ZyCoV-D — has received the subject expert committee (SEC) approval for a two-dose regimen, according to sources close to the development.

The pharmaceutical company, however, declined to comment on the matter.

Approval for the two-dose regimen may boost the offtake of the vaccine not yet available in the private market.

Zydus Lifesciences supplies its three-dose deoxyribonucleic acid (DNA) vaccine — ZyCoV-D — to the Centre at Rs 265 per dose and the needle-free applicator device at Rs 93 per dose. It had an order for 10 million doses from